# Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma

> **NCT00498927** · PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 47 (actual)

## Conditions studied

- Brain and Central Nervous System Tumors

## Interventions

- **DRUG:** temozolomide
- **GENETIC:** protein expression analysis
- **GENETIC:** reverse transcriptase-polymerase chain reaction
- **OTHER:** diagnostic laboratory biomarker analysis
- **OTHER:** immunoenzyme technique

## Key facts

- **NCT ID:** NCT00498927
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-06
- **Primary completion:** 2013-12
- **Final completion:** 2013-12
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2016-02-29

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00498927

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00498927, "Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma". Retrieved via AI Analytics 2026-08-02 from https://api.ai-analytics.org/clinical/NCT00498927. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*